Top Banner
CAT No CAS No MW : : : : MF CAT No CAS No MW : : : : MF CAT No CAS No MW : : : : MF CAT No CAS No MW : : : : MF CAT No CAS No MW : : : : MF CAT No CAS No MW : : : : MF CAT No CAS No MW : : : : MF CAT No CAS No MW : : : : MF CAT No CAS No MW : : : : MF Desvenlafaxine For more information on our products custom synthesis, contact SynZeal today. [email protected] www.synzeal.com SZ-D039001 Desvenlafaxine 93413-62-8 C16H25NO2 263.4 SZ-D039002 Desvenlafaxine Anhydro Impurity 1346600-38-1 C16H23NO 245.4 SZ-D039003 Desvenlafaxine N,N-Didesmethyl Impurity 149289-29-2 C14H21NO2 235.3 SZ-D039005 Desvenlafaxine N-Oxide NA C15H23NO2 249.4 SZ-D039006 Desvenlafaxine Phenol Impurity 539-15-1 C10H15NO 165.2 SZ-D039007 Desvenlafaxine R-Isomer 142761-11-3 C16H25NO2 263.4 SZ-D039008 Desvenlafaxine S-Isomer 142761-12-4 C16H25NO2 263.4 SZ-D039009 Desvenlafaxine Spiro Impurity 1346601-55-5 C16H23NO2 ; HCl 261.4; 36.5 SZ-D039010 Desvenlafaxine Succinate 448904-47-0 C20H31NO6 381.5 SynZeal Research offers all Desvenlafaxine related impurities which certified COA with all characterization data like IR, Mass, HPLC purity,NMR & TGA report. We also provide CMR, DEPT and detailed structurecharacterization report as perrequirements. Desvenlafaxine related products are being used by major pharmaceutical companies across the globe for their ANDA/DMF filing. Desvenlafaxine (O-desmethylvenlafaxine) the major active metabolite of venlafaxine, is an antidepressant from the serotonin- norepinephrine reuptake inhibitor (SNRI class). Desvenlafaxine may be used to treat major depressive disorder and is being studied for use in the management of vasomotor symptoms in postmenopausal women. It is formulated as an extended release tablet. FDA approved in 2008.
1

Desvenlafaxine - Synzeal Catalouge... · 2019-05-03 · Desvenlafaxine (O-desmethylvenlafaxine) the major active metabolite of venlafaxine, is an antidepressant from the serotonin-norepinephrine

Feb 26, 2020

Download

Documents

dariahiddleston
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1: Desvenlafaxine - Synzeal Catalouge... · 2019-05-03 · Desvenlafaxine (O-desmethylvenlafaxine) the major active metabolite of venlafaxine, is an antidepressant from the serotonin-norepinephrine

CAT No

CAS No

MW

:

:

:

:MF

CAT No

CAS No

MW

:

:

:

:MF

CAT No

CAS No

MW

:

:

:

:MF

CAT No

CAS No

MW

:

:

:

:MF

CAT No

CAS No

MW

:

:

:

:MF

CAT No

CAS No

MW

:

:

:

:MF

CAT No

CAS No

MW

:

:

:

:MF

CAT No

CAS No

MW

:

:

:

:MF

CAT No

CAS No

MW

:

:

:

:MF

Desvenlafaxine

For more information on our products custom synthesis, contact SynZeal today.

[email protected] www.synzeal.com

SZ-D039001

Desvenlafaxine

93413-62-8

C16H25NO2

263.4

SZ-D039002

Desvenlafaxine Anhydro Impurity

1346600-38-1

C16H23NO

245.4

SZ-D039003

Desvenlafaxine N,N-Didesmethyl Impurity

149289-29-2

C14H21NO2

235.3

SZ-D039005

Desvenlafaxine N-Oxide

NA

C15H23NO2

249.4

SZ-D039006

Desvenlafaxine Phenol Impurity

539-15-1

C10H15NO

165.2

SZ-D039007

Desvenlafaxine R-Isomer

142761-11-3

C16H25NO2

263.4

SZ-D039008

Desvenlafaxine S-Isomer

142761-12-4

C16H25NO2

263.4

SZ-D039009

Desvenlafaxine Spiro Impurity

1346601-55-5

C16H23NO2 ; HCl

261.4; 36.5

SZ-D039010

Desvenlafaxine Succinate

448904-47-0

C20H31NO6

381.5

SynZeal Research offers all Desvenlafaxine related impurities which certified COA with all characterization data like IR, Mass, HPLC purity,NMR & TGA report. We also provide CMR, DEPT and detailed structurecharacterization report as perrequirements. Desvenlafaxine related products are being used by major pharmaceutical companies across the globe for their ANDA/DMF filing.

Desvenlafaxine (O-desmethylvenlafaxine) the major active metabolite of venlafaxine, is an antidepressant from the serotonin-norepinephrine reuptake inhibitor (SNRI class). Desvenlafaxine may be used to treat major depressive disorder and is being studied for use in the management of vasomotor symptoms in postmenopausal women. It is formulated as an extended release tablet. FDA approved in 2008.